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Anyone who makes The New York Times
an obligatory read - particularly the busi-
ness and technology sections would have
spotted the masterly piece on the Chinese
currency “floating for all of 20 minutes” on
the afternoon of April 29, at a time when
European economies were looking for-
wards to a long bank holiday weekend or
traditional Mayday rallies.
“No one knows for sure if the move was
deliberate or a result of a technical glitch”,
wrote Keith Bradsher, “but the yuan (or
renminbi) suddenly broke out of its pre-
scribed trading range.”
“It climbed until it took 8.270 of them to
buy a dollar instead of the usual 8.276.
That difference, of only six thousandths of
a yuan, might not seem like much of a
change… [but] the brief appreciation, a
hint of further rises if the yuan were to
float, was enough to roil currency markets
around the world.”
“The dollar fell and the euro, yen and gold
rose, as investors placed bets that if China
let the yuan rise against the dollar, other
countries would also permit their curren-
cies to appreciate against the dollar
because their exporters would no longer
be so fearful of being undercut by Chinese
rivals.”
“ ‘I wouldn't be surprised if we woke up to
an announcement this weekend; I would
n't be surprised if they waited until this
summer,’ said Jonathan Anderson, an
economist at UBS.’”
Truly interesting financial times when
someone plays mahjong with nano-mov-
ments of the yuan. 
A month earlier, Lux Research quietly
added its Lux Nanotech Index to the New
York Stock Exchange, 11 months after
Merill Lynch posted theirs, after a bit of
revision. The Lux approach is to separate
nanotech specialists and end-users.
So, the two indexes hold in common
Flamel Technologies, Skyepharma Plc,
Headwaters Inc, Pharmacopeia Inc,
Westaim Corp, Biosante Pharmaceuticals,
Veeco Instruments, Harris & Harris Group,
Nanophase Technologies, Fei Co, Altair
Nanotechnologies, NVE Corp and
Immunicon.
Then comes divergence. Lux Research
adds Amer Pharmaceutical Ptnrs, General
Motors, HP, General Electric, Air Products,
Dupont DeNemours, NEC Crop, 3M, BASF
and IBM. Merill Lynch included Ultratech
Inc, MTS Systems, Symyx Technologies,
Kopin, Amcol International, Lumera Corp,
Acacia Research-Combimatrix, Cabot
Corp, Nanogen Inc, JMAR Technologies,
Arrow-head Research and Novavax Inc.
Well, it seems that both yuan watching
and the indexes game, like a good malt,
get more interesting as they mature.
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